Cochrane · systematic review · CD013167
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
Roberts, KE, Adsett, IT, Rickett, K, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 8 · 61.5%Low 5 · 38.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table ‐ Systemic therapy compared to control for treating aromatase inhibitor‐induced musculoskeletal symptoms in women with early breast cancer
Population: women with early breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in pain from baseline to end of intervention Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 2 studies · 183 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Change in grip strength from baseline to end of intervention Summary of findings table ‐ Systemic therapy vs control | RR 1.08 [0.37, 3.17] | 1 study · 137 participants | Low Downgraded: imprecision, indirectness |
Safety of systemic therapies in AIMSS Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 4 studies · 344 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Effect on discontinuation of aromatase inhibitors (AI) Summary of findings table ‐ Systemic therapy vs control | RR 0.16 [0.01, 2.99] | 1 study · 147 participants | Low Downgraded: imprecision, indirectness |
Effect on breast cancer‐specific quality of life (BCS‐QoL) Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 1 study · 44 participants | Low Downgraded: risk of bias, imprecision |
Health‐related quality of life (HRQoL) ‐ HRQoL: Total Functional Assessment of Cancer Therapy – General(FACT‐G) score Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 1 study · 1 participants | Low Downgraded: risk of bias, imprecision |
Incidence of AIMSS Summary of findings table ‐ Systemic therapy vs control | RR 0.82 [0.63, 1.06] | 2 studies · 240 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Summary of findings table ‐ Systemic therapy compared to control for preventing aromatase inhibitor‐induced musculoskeletal symptoms in women with early breast cancer
Population: health problem or population
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in pain from baseline to end of intervention Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 10 studies · 1099 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Change in stiffness from baseline to end of intervention Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 4 studies · 295 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Grip strength ‐ Vitamin D Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 1 study · 1 participants | Low Downgraded: imprecision, indirectness |
Effect on breast cancer‐specific quality of life (BCS‐QoL) Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 2 studies · 147 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Effect on health‐related quality of life (HRQoL) Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 3 studies · 208 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Safety of systemic therapies for the treatment of AIMSS Summary of findings table ‐ Systemic therapy vs control | no estimate extracted | 10 studies · 1250 participants | Very low Downgraded: risk of bias, imprecision, publication bias |